statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Amneal Pharmaceuticals settles $270 million opioid crisis agreement, offering cash and naloxone spray. Boosted by strong Q1 earnings, the company reaffirms fiscal guidance.
read more...

Generic Drugmaker Amneal Announces Over $270M In US Opioid Lawsuit Settlement

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (Amneal or the Company) announced its results today for the first quarter ended March 31, 2024. We are extremely pleased with our outstanding start to the...

Amneal Reports First Quarter 2024 Financial Results

Amneal Pharmaceuticals will sell naloxone to California for $24 per pack, or about 40% cheaper than the market rate. Read More...

California partners with pharma firm on generic Narcan amid opioid crisis

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (Amneal or the Company) today announced the launch of PEMRYDI RTU, the first and only ready-to-use presentation of pemetrexed for injection. This product...

Amneal Launches PEMRYDI RTU, the First Ready-to-Use Version of Important Oncology Injectable Medicine

Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its first quarter 2024 financial results on Friday, May 3, 2024, prior to market open. The Company will host...

Amneal to Report First Quarter 2024 Results on May 3, 2024

Lauren Clason | (TNS) CQ-Roll Call
A recent tweak to a Medicaid formula could be behind the shake-up to inhaler products, a series of changes that have both benefited and harmed patients with asthma...

Experts say Medicaid rebate change is behind inhaler price cuts

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (Amneal or the Company), a global pharmaceutical company, today announced that Chirag and Chintu Patel, Co-founders and Co-Chief Executive Officers, will...

Amneal to Ring the Nasdaq Closing Bell on April 2, 2024

Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (Amneal or the Company) today announced it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA...

Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension

This is a signal that AMRX's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Amneal Pharmaceuticals (AMRX, $6.07) RSI Indicator left the overbought zone on March 22, 2024

Amneal Pharmaceuticals (AMRX, $6.3) RSI Indicator left the overbought zone on March 21, 2024

Amneal Pharmaceuticals, Inc. is a medicine company, which engages in the provision of pharmaceuticals. Its product portfolio includes generics, specialty, biosciences, and product catalog. It operates through the following segments: Generics, Specialty, and AvKARE. The Generics segment relates to oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, and transdermal patches and topicals. The Specialty segment refers to the development, promotion, sale, and distribution of proprietary branded pharmaceutical products. The AvKARE segment provides pharmaceuticals, medical, and surgical products and services to governmental agencies. The company was founded by Chirag K. Patel and Chintu Patel in 2002 and is headquartered in Bridgewater, NJ.

Volume	318,798.00
52-Wk High	$6.90
52-Wk Low	$1.74

Period	Estimated	Reported	Surprise	Result
Q2'24	$0.14	--	--	N/A
Q1'24	$0.09	$0.14	52.07%	BEAT
Q4'23	$0.07	$0.14	90.04%	BEAT
Q3'23	$0.13	$0.19	49.84%	BEAT
Q2'23	$0.10	$0.19	91.92%	BEAT

AMRX Amneal Pharmaceuticals Inc - Ordinary Shares - Class A

About

Feed

News

Sentiment

Earnings

Fundamentals